[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637987":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":18,"id":47,"slug":18,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":18,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":18,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":18,"overallStatus":31,"whyStopped":18,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"University of Minnesota","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Elevated Pacemaker Rate","EXPERIMENTAL","CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.",[13],"Other: Pacemaker Rate",[15],{"type":6,"name":16,"description":11,"armGroupLabels":17,"otherNames":18},"Pacemaker Rate",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Valmiki Maharaj","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Meghan Muscala","CONTACT","612-626-5863","payne324@umn.edu",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Minneapolis","Minnesota","55455","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-93.26384,44.97997,{"lat":41,"lon":40},[44],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},{"type":46,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100637987",false,"NCT07583823","Elevated Rate Pacing of Cardiac Amyloidosis","Inclusion Criteria:\n\n* Adults 18 and older\n* Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: \"2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee\n* Implanted Cardiac Pacemaker (+\u002F- Defibrillator)\n* Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation\n* Non-dilated left ventricle by echocardiography\n* Ability to provide written consent\n* English Speaking\n\nExclusion Criteria:\n\n* Paced QRS duration of \\>150 ms (indicator for pacing mediated dyssynchrony)\n* Dilated left ventricle","ALL","18 Years",{"count":55,"type":56},10,"ESTIMATED","INTERVENTIONAL",[59],"NA","This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.",[62,63],"Cardiac Amyloidosis","Pacemaker","2026-05-06",{"date":66,"type":67},"2026-05-13","ACTUAL",{"date":69,"type":67},"2025-10-10",{"date":71,"type":56},"2026-10-10",{"name":5,"class":6},1]